Tectorigenin inhibits inflammatory responses in murine inflammatory bowel disease and LPS‐stimulated macrophages via inactivating MAPK signaling pathway
Open Access
- 9 May 2024
- journal article
- research article
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 12 (5) , e1077
Abstract
Background: Considering the antihepatitis effects of Tectorigenin (TEC), and the same adenosine mitogen‐activated protein kinase (MAPK) pathway in both hepatitis and inflammatory bowel disease (IBD) models, exploring the role of TEC in IBD is contributive to develop a new treatment strategy against IBD.Methods: The IBD mouse model was constructed by feeding with dextran sodium sulfate (DSS) and injection of TEC. Afterward, the mouse body weight, colon length, and disease activity index (DAI) were tested to assess the enteritis level. Mouse intestine lesions were detected by hematoxylin and eosin staining. Murine macrophages underwent lipopolysaccharide (LPS) induction to establish an inflammation model. Cell viability was determined by cell counting kit‐8 assay. Enzyme‐linked immunosorbent assay was performed to measure interleukin 6 (IL‐6) and tumor necrosis factor‐α (TNF‐α) levels. Cyclooxygenase‐2 (COX‐2) and inducible nitric oxide synthase (iNOS) expressions were quantified via quantitative reverse transcription polymerase chain reaction. Levels of MAPK pathway‐related proteins (p‐P38, P38, p‐Jun N‐terminal kinase (JNK), JNK, signal‐regulated kinase (ERK), p‐ERK), COX‐2 and iNOS were quantitated by Western blot.Results: TEC improved the inflammatory response through ameliorating weight loss, shortening colon, and increasing DAI score in IBD mouse. Expressions of intestinal inflammatory factors (IL‐6, TNF‐α, iNOS and COX‐2) and MAPK pathway‐related proteins (p‐P38, p‐JNK, and p‐ERK) were increased both in DSS‐induced mouse intestinal tissue, but TEC inhibited expressions of inflammatory factors. The same increased trend was identified in LPS‐induced macrophages, but TEC improved macrophage inflammation, as evidenced by downregulation of inflammatory factors.Conclusion: TEC mitigates IBD and LPS‐induced macrophage inflammation in mice via inhibiting MAPK signaling pathway.Keywords
This publication has 30 references indexed in Scilit:
- Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic TherapiesImmune Network, 2017
- 5-Azacytidine regulates matrix metalloproteinase-9 expression, and the migration and invasion of human fibrosarcoma HT1080 cells via PI3-kinase and ERK1/2 pathwaysInternational Journal of Oncology, 2016
- Pathological roles of MAPK signaling pathways in human diseasesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- A phenolic acid phenethyl urea compound inhibits lipopolysaccharide-induced production of nitric oxide and pro-inflammatory cytokines in cell cultureInternational Immunopharmacology, 2010
- Xanthorrhizol inhibits 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation and two-stage mouse skin carcinogenesis by blocking the expression of ornithine decarboxylase, cyclooxygenase-2 and inducible nitric oxide synthase through mitogen-activated protein kinases and/or the nuclear factor- BCarcinogenesis, 2007
- NF-κB activation as a pathological mechanism of septic shock and inflammationAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Macrophages in InflammationCurrent Drug Targets - Inflammation & Allergy, 2005
- Nuclear Factor–κB and Its Role in Sepsis‐Associated Organ FailureThe Journal of Infectious Diseases, 2003
- Oxidant signals and oxidative stressCurrent Opinion in Cell Biology, 2003
- Urinary excretion of podocytes in patients with sepsis.1999